Pacific Cancer Care to use Deep Lens’ AI solutions for clinical trials
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

Pacific Cancer Care to use Deep Lens’ AI solutions for clinical trials

11 Oct 2021 (Last Updated October 11th, 2021 12:24)

Deep Lens’ VIPER solution can aid in automating the selection of eligible subjects during diagnosis and match them to trials. 

Pacific Cancer Care to use Deep Lens’ AI solutions for clinical trials
Deep Lens’ solution is offered for free to oncology practices. Credit: National Cancer Institute on Unsplash.

Pacific Cancer Care will use Deep Lens’ artificial intelligence (AI)-based solutions to streamline its clinical trial matching and expedite enrolment for cancer patients after the companies entered a partnership.

The collaboration will extend Pacific Cancer Care’s current clinical trial offering to people by precisely and efficiently detecting eligible patients for trials, boosting communications between patient care groups and taking more trials to the practice.

According to estimates, more than 15,000 cancer trials are actively enrolling subjects, but less than one in 30 patients take part in a trial.

Reduced trial site resources make it time-consuming to detect eligible subjects, especially when the complexity of the trial protocols rises.

Deep Lens’ AI solution VIPER automates the process of detecting potentially eligible subjects during diagnosis and matches them to related trials and offers support to care teams.

By pre-screening all patients from EMR (OncoEMR) of Pacific Cancer Care, VIPER can merge molecular data feeds from Caris Life Sciences, Foundation Medicine and Guardant Health, and all pathology feeds to automatically find qualified subjects for trials.

The pre-screening and trial matching solution of Deep Lens is offered at zero cost to oncology practices.

Pacific Cancer Care oncologist Zach Koontz said: “Clinical trials are not only critical to the advancement of new therapeutic options for cancer, but they present a unique opportunity for patients to access novel treatments well in advance of their commercialization, some of which may help positively impact the state of their disease.

“We are excited to partner with Deep Lens to broaden our clinical research program through an increased number of trials that we can offer onsite and by expediting the time we can get patients into these trials.”

In June this year, the Center for Cancer and Blood Disorders (The CenterTX) in the US announced plans to deploy Deep Lens’ AI-based clinical trial screening and enrolment solution VIPER.